Sign in

CIK 0001711279

  • Large accelerated filer

Krystal Biotech, Inc.

Sign in to watch
Ticker
KRYS
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
FY end
Dec 31
Entity type
Operating
EIN
821080209
Phone
+1 412-586-5830
Business address
2100 WHARTON STREET, SUITE 701, PITTSBURGH, PA, 15203
  1. 4 Shares withheld for taxes President and CEO gave up 30,584 shares (to pay taxes)
  2. 4 Planned sale Director sold 11,803 shares at an average $275.59 ($3,252,824)
  3. 4 Planned sale Director sold 60,161 shares at an average $268.44 ($16,149,383)
  4. 4 Open-market sale Director sold 18,950 shares at an average $261.41 ($4,953,694)
  5. 4 Planned sale Chief Accounting Officer sold 12,500 shares at an average $272.14 ($3,401,705)
  6. 4 Planned sale President, R&D sold 50,000 shares at an average $220.15 ($11,007,333)
  7. 4 Planned sale President and CEO sold 50,000 shares at an average $220.15 ($11,007,447)
  8. 4 Planned sale President, R&D sold 35,873 shares at an average $150.39 ($5,395,001)
  9. 4 Planned sale President and CEO sold 35,873 shares at an average $150.39 ($5,395,001)
  10. 4 Planned sale President, R&D sold 14,127 shares at an average $150.27 ($2,122,835)
  11. 4 Planned sale President and CEO sold 14,127 shares at an average $150.27 ($2,122,835)
  12. 4 Derivatives Options or other derivatives
  13. 4 Derivatives Options or other derivatives
  14. 4 Derivatives Options or other derivatives
  15. 4 Derivatives Options or other derivatives
  16. 4 Derivatives Options or other derivatives
  17. 4 Derivatives Options or other derivatives
  18. 4 Planned sale President, R&D sold 50,000 shares at an average $177.79 ($8,889,525)
  19. 4 Planned sale President and CEO sold 50,000 shares at an average $177.79 ($8,889,525)
  20. 4 Planned sale Chief Accounting Officer sold 750 shares at $175.22 ($131,415)

Page 2 of 10 · 186 filings